Contact
searchSearch
HMP Global

Hepatology News

Research Highlights
GLP-1 RAs Linked to Lower Risk of Hepatic Complications in MASLD and T2D
06/11/2026
Jessica Garlewicz
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found...
06/11/2026
Gastroenterology
FDA Approval
FDA Approves Bulevirtide for Hepatitis D Treatment
06/01/2026
Rebecca Mashaw
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first...
06/01/2026
Gastroenterology
Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
FDA Alert
FDA Approves Linerixibat for Pruritis in PBC
03/20/2026
Rebecca Mashaw
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug...
03/20/2026
Gastroenterology
Research Highlights
Dynamic FIB-4 Changes Track Fibrosis Progression and Predict Outcomes in MASLD
03/18/2026
Jessica Garlewicz
Findings of a recent analysis suggest that serial FIB-4 monitoring may provide prognostic value beyond a single baseline measurement.
Findings of a recent analysis suggest that serial FIB-4 monitoring may provide prognostic value beyond a single baseline measurement.
Findings of a recent analysis...
03/18/2026
Gastroenterology
Identification of Fibrosis
Machine Learning Tool Improves Noninvasive Identification of F2 Fibrosis in MASH
02/17/2026
Jessica Garlewicz
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based...
02/17/2026
Gastroenterology
Research Review
Alcohol Abstinence Enables Hepatic Recompensation in One-Third of Patients With Decompensated Cirrhosis
02/17/2026
Jessica Garlewicz
The findings underscore the potential for meaningful disease regression when alcohol cessation is achieved early.
The findings underscore the potential for meaningful disease regression when alcohol cessation is achieved early.
The findings underscore the...
02/17/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Drug Safety
UDCA Use Linked to Lower Cancer Risk in Primary Biliary Cholangitis, Large EHR Study Finds
01/14/2026
Jessica Garlewicz
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing gastroenterologists, the key takeaway is that early UDCA initiation in PBC appears not only safe from an oncologic perspective but may be associated with lower risk of certain cancers.
For practicing...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology

News

Research Highlights
GLP-1 RAs Linked to Lower Risk of Hepatic Complications in MASLD and T2D
06/11/2026
Jessica Garlewicz
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found...
06/11/2026
Gastroenterology
Research Insights
IBS-C Microbiome Signatures Offer Insights Into Parkinson’s-Related Constipation
06/09/2026
Rebecca Mashaw
New research highlights important similarities and differences between IBS-C and Parkinson’s disease–associated constipation
New research highlights important similarities and differences between IBS-C and Parkinson’s disease–associated constipation
New research highlights...
06/09/2026
Gastroenterology
Research Review
Colonoscopy Associated With Lower Colorectal Cancer Risk in Adults Aged 40–49 Years
06/03/2026
Jessica Garlewicz
Investigators observed a lower cumulative incidence of CRC among individuals who underwent colonoscopy across both age groups studied.
Investigators observed a lower cumulative incidence of CRC among individuals who underwent colonoscopy across both age groups studied.
Investigators observed a lower...
06/03/2026
Gastroenterology
Research Insights
Early-Onset Colorectal Cancer Survivors Report Persistent Sexual Health Challenges
05/27/2026
Rebecca Mashaw
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing...
05/27/2026
Gastroenterology
Research Review
Synchronous Colon Cancer Not Associated With Worse Survival in Stage I–III Disease
05/27/2026
Jessica Garlewicz
The findings provide reassurance regarding prognosis in patients presenting with multiple primary tumors.
The findings provide reassurance regarding prognosis in patients presenting with multiple primary tumors.
The findings provide reassurance...
05/27/2026
Gastroenterology
Research Review
High Rehospitalization and Mortality Rates Persist After ICI-Associated Colitis
05/06/2026
Jessica Garlewicz
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained...
05/06/2026
Gastroenterology
Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
News
Lifetime Alcohol Intake Linked to Colorectal Cancer Risk
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use